Xeris Pharmaceuticals Inc (XERS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.04B
Last updated: Nov 17, 2026 at 11:06 AM ET
Xeris Pharmaceuticals Inc (XERS) Earnings: Report Dates and Results
Xeris Pharmaceuticals (XERS) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Xeris Pharmaceuticals reported EPS of $0.06, above the $0.02 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
XERS has an expected report date of Mar 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 33.3% below the $0.06 reported for the quarter ended Dec 31, 2025.
XERS Earnings Call
The latest XERS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 34 quarters below that had an estimate, XERS beat 14, missed 18 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $107.22M, up 44.2% from $74.38M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.06 | $0.02 | $0.01 - $0.04 | +200.00% | Beat | +1614.3% | 3 | 0 up, 1 down | Nov 5, 2026 | $107.22M |
| Jun 30, 2026 | -$0.01 | $0.02 | -$0.01 - $0.02 | -150.00% | Miss | N/A | 3 | 1 up, 0 down | Aug 6, 2026 | $92.10M |
| Mar 31, 2026 | $0.01 | -$0.01 | -$0.02 - $0.01 | +200.00% | Beat | N/A | 3 | 0 up, 0 down | May 7, 2026 | $83.13M |
| Dec 31, 2025 | $0.06 | $0.02 | $0.02 - $0.07 | +261.45% | Beat | N/A | 2 | 1 up, 0 down | Mar 2, 2026 | $85.81M |
| Sep 30, 2025 | $0.00 | $0.01 | -$0.02 - $0.03 | -65.00% | Miss | N/A | 3 | 1 up, 0 down | Nov 6, 2025 | $74.38M |
| Jun 30, 2025 | -$0.01 | -$0.03 | -$0.03 - -$0.03 | +66.67% | Beat | N/A | 1 | 1 up, 0 down | Aug 7, 2025 | $71.54M |
| Mar 31, 2025 | -$0.06 | -$0.04 | -$0.04 - -$0.04 | -50.00% | Miss | N/A | 1 | 0 up, 0 down | May 8, 2025 | $60.12M |
| Dec 31, 2024 | -$0.03 | -$0.02 | -$0.03 - -$0.01 | -50.00% | Miss | N/A | 2 | 1 up, 0 down | Mar 6, 2025 | $60.10M |
| Sep 30, 2024 | -$0.06 | -$0.08 | -$0.10 - -$0.06 | +25.00% | Beat | N/A | 6 | 0 up, 0 down | Nov 8, 2024 | $54.27M |
| Jun 30, 2024 | -$0.10 | -$0.09 | -$0.12 - -$0.09 | -11.11% | Miss | N/A | 6 | 1 up, 0 down | Aug 8, 2024 | $48.06M |
| Mar 31, 2024 | -$0.14 | -$0.11 | -$0.14 - -$0.11 | -27.27% | Miss | N/A | 6 | 0 up, 0 down | May 9, 2024 | $40.64M |
| Dec 31, 2023 | -$0.10 | -$0.10 | -$0.13 - -$0.07 | 0.00% | In line | N/A | 5 | 1 up, 0 down | Mar 6, 2024 | $44.39M |
| Sep 30, 2023 | -$0.09 | -$0.10 | -$0.13 - -$0.09 | +10.00% | Beat | N/A | 5 | 0 up, 0 down | Nov 9, 2023 | $48.32M |
| Jun 30, 2023 | -$0.14 | -$0.11 | -$0.15 - -$0.11 | -27.27% | Miss | N/A | 4 | 0 up, 0 down | Aug 8, 2023 | $38.01M |
| Mar 31, 2023 | -$0.12 | -$0.15 | N/A | +20.00% | Beat | N/A | 4 | 0 up, 0 down | May 9, 2023 | $33.20M |
| Dec 31, 2022 | -$0.10 | -$0.16 | -$0.18 - -$0.14 | +37.50% | Beat | N/A | 4 | 0 up, 0 down | Mar 8, 2023 | $33.14M |
| Sep 30, 2022 | -$0.16 | -$0.15 | -$0.19 - -$0.15 | -6.67% | Miss | N/A | 4 | 1 up, 0 down | Nov 9, 2022 | $29.73M |
| Jun 30, 2022 | -$0.19 | -$0.22 | N/A | +13.64% | Beat | N/A | N/A | 0 up, 0 down | Aug 10, 2022 | $25.31M |
| Mar 31, 2022 | -$0.25 | -$0.24 | -$0.28 - -$0.22 | -4.17% | Miss | N/A | 5 | 0 up, 1 down | May 11, 2022 | $22.07M |
| Dec 31, 2021 | -$0.42 | -$0.24 | -$0.38 - -$0.17 | -75.00% | Miss | N/A | 5 | 0 up, 0 down | Mar 10, 2022 | $21.57M |
| Sep 30, 2021 | -$0.39 | -$0.37 | -$0.39 - -$0.32 | -5.41% | Miss | N/A | 3 | 0 up, 0 down | Nov 10, 2021 | $11.06M |
| Jun 30, 2021 | -$0.41 | -$0.30 | -$0.34 - -$0.27 | -36.67% | Miss | N/A | 3 | N/A | Aug 5, 2021 | $8.91M |
| Mar 31, 2021 | -$0.30 | -$0.34 | -$0.41 - -$0.31 | +11.76% | Beat | N/A | 4 | N/A | May 13, 2021 | $8.05M |
| Dec 31, 2020 | -$0.41 | -$0.38 | -$0.42 - -$0.31 | -7.89% | Miss | N/A | 5 | N/A | Mar 9, 2021 | $7.17M |
| Sep 30, 2020 | -$0.35 | -$0.52 | -$0.57 - -$0.47 | +32.69% | Beat | N/A | 5 | N/A | Nov 9, 2020 | $9.40M |
| Jun 30, 2020 | -$0.63 | -$0.73 | -$0.80 - -$0.65 | +13.70% | Beat | N/A | 5 | N/A | Aug 10, 2020 | $2.03M |
| Mar 31, 2020 | -$0.89 | -$0.89 | -$1.11 - -$0.81 | 0.00% | In line | N/A | 5 | N/A | May 7, 2020 | $1.79M |
| Dec 31, 2019 | -$1.23 | -$1.13 | -$1.31 - -$0.90 | -8.85% | Miss | N/A | 5 | N/A | Mar 11, 2020 | $1.86M |
| Sep 30, 2019 | -$1.22 | -$1.23 | -$1.36 - -$1.16 | +0.81% | Beat | N/A | 4 | N/A | Nov 7, 2019 | $323000 |
| Jun 30, 2019 | -$1.28 | -$0.94 | -$0.98 - -$0.87 | -36.17% | Miss | N/A | 4 | N/A | Aug 6, 2019 | $320000 |
| Mar 31, 2019 | -$1.07 | -$0.76 | -$0.92 - -$0.68 | -40.79% | Miss | N/A | 4 | N/A | May 9, 2019 | $248000 |
| Dec 31, 2018 | -$0.98 | -$0.93 | -$1.22 - -$0.80 | -5.38% | Miss | N/A | 4 | N/A | Mar 6, 2019 | $801000 |
| Sep 30, 2018 | -$0.71 | -$0.78 | -$0.97 - -$0.71 | +8.97% | Beat | N/A | 4 | N/A | Nov 7, 2018 | $582000 |
| Jun 30, 2018 | -$3.07 | -$0.88 | -$1.13 - -$0.66 | -248.86% | Miss | N/A | 4 | N/A | Aug 13, 2018 | $819000 |
| Mar 31, 2018 | -$4.69 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 21, 2018 | $263000 |
| Dec 31, 2017 | -$1.29 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2018 | $467000 |
| Sep 30, 2017 | -$4.43 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2017 | $170000 |
| Jun 30, 2017 | -$3.72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2017 | $565000 |
| Mar 31, 2017 | -$0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2017 | $354000 |
| Dec 31, 2016 | -$2.29 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2017 | $1.07M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.01, after -$0.33 the year before. It was -$2.29 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.01 | N/A |
| Dec 31, 2024 | -$0.33 | N/A |
| Dec 31, 2023 | -$0.45 | N/A |
| Dec 31, 2022 | -$0.70 | N/A |
| Dec 31, 2021 | -$1.52 | N/A |
| Dec 31, 2020 | -$2.28 | N/A |
| Dec 31, 2019 | -$4.80 | N/A |
| Dec 31, 2018 | -$9.45 | N/A |
| Dec 31, 2017 | -$9.67 | N/A |
| Dec 31, 2016 | -$2.29 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,300 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,261 | 9 | |
| 2026Q2 | Jun 30, 2026 | 4,550 | 10 | |
| 2026Q1 | Mar 31, 2026 | 3,573 | 9 | |
| 2025Q4 | Dec 31, 2025 | 4,571 | 11 | |
| 2025Q3 | Sep 30, 2025 | 4,062 | 10 | |
| 2025Q2 | Jun 30, 2025 | 3,106 | 8 | |
| 2025Q1 | Mar 31, 2025 | 3,468 | 8 | |
| 2024Q4 | Dec 31, 2024 | 5,670 | 10 |
2026Q3 Earnings Call
Opening remarks
Cristi Barnett Vice President of Investor Relations Thank you, Bella. Good morning, everyone, and welcome to Xeris Biopharma's Third Quarter 2026 Financial Results Conference Call. Earlier this morning, we issued a press release detailing our third quarter 2026 financial and operating results. This press release can be found on our website at xerispharma.com. Joining me on today's call are John Shannon, our Chairman and Chief Executive Officer, and Steve Pieper, our Chief Financial Officer. Following our prepared remarks, we will open the call for your questions. Before we begin, I'd like to remind you that today's discussion will include forward-looking statements regarding Xeris' future expectations, plans, strategies, objectives, and financial performance, including our full year 2026 financial guidance and our 2030 outlook. These forward-looking statements are based on management's current assumptions and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied. For a discussion of these risks and uncertainties, please refer to the risk factors described in our filings with the SEC, including our most recent annual report on Form 10-K and our subsequent filings with the SEC, as well as the forward-looking statements disclaimer in our earnings release. In addition, during today's call, we will reference certain financial measures that are presented on a non-GAAP basis. A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is included in our earnings release. Before I turn it over to John, I'd like to briefly introduce myself. I'm Cristi Barnett, and I recently joined Xeris to lead investor relations following Allison Wey's retirement. Some of you may know me from my previous companies, and for those who I haven't yet met, I look forward to connecting and working with you. We will miss Allison here at Xeris, and I'm pleased to carry the investor relations baton forward. I look forward to an open dialogue and to keeping you informed about Xeris' progress. With that, I'll turn it over to John.
John Shannon Chairman and CEO Thank you, Cristi, and welcome to Xeris. We are happy to have you on the team. Good morning, everyone. I am pleased to report that Xeris had a spectacular third quarter, and we now see our company on a new growth curve, one that is both accelerating our near-term financial outlook and redefining what we believe is possible for this company. Importantly, this new trajectory reflects expected growth from the entire enterprise, Recorlev, Gvoke, and KEVEYIS. Total revenue grew more than 44% year-over-year, led by Recorlev, where the expanded commercial team moved from build to yield and delivered record referrals and new patient starts. Gvoke delivered a better-than-expected back-to-school prescription lift, and prescription demand is back in solid growth mode.
Frequently Asked Questions About XERS
When is Xeris Pharmaceuticals's next earnings date?
Xeris Pharmaceuticals's next earnings report is expected for Mar 1, 2027.
Did XERS beat earnings estimates last quarter?
Yes. Xeris Pharmaceuticals reported EPS of $0.06 for the quarter ended Sep 30, 2026, above the $0.02 estimate, a 200.00% surprise.
What EPS do analysts expect from XERS next quarter?
The consensus EPS estimate for Xeris Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.04 from 9 analysts, with estimates from $0.00 to $0.06.
How often does XERS beat earnings estimates?
Xeris Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +51.64%.
XERS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors